ArticleThe Journal of clinical and aesthetic dermatology2026
Real-World Effectiveness and Safety of Tildrakizumab in Patients With Moderate-to-Severe Psoriasis After Failure of Ustekinumab: A Multicenter Retrospective Study.
Article in The Journal of clinical and aesthetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the effectiveness and safety of switching to tildrakizumab, a selective interleukin (IL) 23p19 inhibitor, in patients with moderate-to-severe plaque psoriasis who had an inadequate response to ustekinumab (IL-12/23 inhibitor) in a real-world setting.
methodsA multicenter retrospective observational study was conducted and included 14 patients who switched to tildrakizumab following ustekinumab failure. Effectiveness was assessed using Psoriasis Area and Severity Index (PASI), Physician Global Assessment (PGA), and Dermatology Life Quality Index (DLQI) at Weeks 0, 12, 28, 36, and 52.
resultsThe cohort (mean age: 45.92 years; 85.7% prior systemic therapy) showed rapid improvement. Mean PASI decreased from 9.36 at baseline to 2.60 at Week 12, maintaining low disease activity through Week 52 with 100% of patients achieving an absolute PASI score <3. Similar trends were observed in PGA and DLQI scores. No new safety signals were identified. LIMITATIONS: This study included a small sample size (n=14) and retrospective design.
conclusionTildrakizumab showed consistent clinical improvement as a rescue therapy for patients after ustekinumab failure, supporting the clinical benefit of switching from p40 to specific p19 inhibition.
Indexed as
Identifiers
42459246PMC13372303What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.